News

Actavis debuts generic Pariet in Europe; Impax challenges Opana ER patent

18-11-2012

Switzerland-based generic drugmaker Actavis, now wholly-owned by the USA's Watson Pharmaceuticals (NYSE:…

ActavisEndo PharmaceuticalsGastro-intestinalsGenericsGrunenthalImpax LaboratoriesJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaOpana ERParietPatentsThoRx LabsWatson Pharmaceuticals

Watson debuts generic Nexium in Europe; Mylan launches Amidate copy in USA

08-08-2012

US generics firm Watson Pharmaceuticals (NYSE: WPI) said yesterday that its third-party business Specifar…

AmidateAstraZenecaEuropeGastro-intestinalsGenericsHospiraMarkets & MarketingMylan LaboratoriesNeurologicalNexiumNorth AmericaRegulationWatson Pharmaceuticals

Watson buys Greek generics firm Specifar for $562 million; Nestle acquires Prometheus

26-05-2011

USA-based Watson Pharmaceuticals (NYSE: WPI) said yesterday that it has acquired Specifar Pharmaceuticals,…

Gastro-intestinalsGenericsMergers & AcquisitionsNestlePharmaceuticalPrometheus LabsSpecifar PharmaceuticalsWatson Pharmaceuticals

US approval of generic Protonix for Actavis and Risperdal for Taro; Watson does not infringe patent

10-02-2011

Iceland headquartered Actavis says that it has received approval from the US Food and Drug Administration…

ActavisGastro-intestinalsGenericsMucinexNeurologicalNorth AmericaPatentsProtonixRegulationRespiratory and PulmonaryRisperdalTaro PharmaceuticalsWatson Pharmaceuticals

COMPANY SPOTLIGHT

Menarini

Back to top